New hope for leukemia patients: targeted drug combo trial launches
Disease control
Recruiting now
This early-stage trial tests a new drug called revumenib added to standard chemotherapy for adults with a specific genetic type of acute myeloid leukemia (AML). The goal is to find a safe dose that improves remission rates. About 22 newly diagnosed patients will participate.
Phase: PHASE1 • Sponsor: Richard Stone, MD • Aim: Disease control
Last updated May 03, 2026 08:54 UTC